Novo Nordisk stock fell nearly 8% in New York trading on Monday after the drugmaker’s Capital Markets Day failed to convince investors that its pipeline can fully replace the extraordinary growth generated by Wegovy and Ozempic as semaglutide approaches the end of its patent-protected life.
The NYSE-listed ADR, NVO, was down 7.86% at around 18:15 GMT on September 21, according to TradingKey, after the selloff had already swept through Copenhagen earlier in the day. Reuters reported that the European-listed shares fell as much as 9% as management faced questions over pricing power, competition and the company’s ability to replace revenue threatened by patent expirations in the early 2030s.
The persistence of the decline through several hours of U.S. cash trading is important. Novo did not present a small pipeline. It laid out ambitions for more than DKK 150 billion, or roughly $23 billion, of risk-adjusted pipeline sales in 2035 and more than five potential “multi-blockbuster” launches by 2030. Investors nevertheless kept selling.
A $23 Billion Pipeline Target Was Not Enough
At its Capital Markets Day in London, Novo said it wants to launch more than five multi-blockbusters by 2030, have at least five Phase 3 programs in obesity and diabetes and at least five more in other therapeutic areas.
The company also set a target of more than DKK 150 billion in risk-adjusted pipeline sales by 2035. Novo’s own announcement makes two qualifications important: the figure includes assets already in the current pipeline, and the targets are strategic ambitions rather than formal financial guidance.
Novo also expects its 2026-2030 revenue compound annual growth rate to be broadly in line with a pharmaceutical peer group that includes Eli Lilly, AstraZeneca, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck, Pfizer and others.
That peer-relative language appears to have been one of the bigger problems for investors accustomed to Novo growing substantially faster than traditional large-cap pharma during the rise of Wegovy.
Jacob Pedersen, investment strategist at Middelfart Sparekasse, told CNBC that benchmarking Novo against such a wide pharmaceutical group implies an ambition level “well below” what investors had historically expected.
That reaction fits the concern FinanceFeeds highlighted in its August Novo Nordisk NVO stock analysis: the market had increasingly stopped trading the company on near-term earnings alone and was instead treating each major update as a referendum on whether the post-semaglutide pipeline can support the valuation.
Semaglutide Is the “Elephant in the Room”
Chief Executive Mike Doustdar did not avoid the central issue.
He described the approaching loss of semaglutide exclusivity as the “elephant in the room.” Semaglutide is the active ingredient in both Wegovy and Ozempic, meaning the patent cliff affects the two franchises most closely associated with Novo’s transformation into a global obesity-treatment leader.
Reuters said key expirations arrive in the early 2030s, with U.S. exclusivity expected to begin expiring around 2032. The timing gives Novo several years to establish successor products, but investors are already trying to determine what pricing, margins and market share look like once branded semaglutide faces cheaper alternatives.
That challenge is becoming harder as Eli Lilly expands its own obesity franchise. Lilly is competing with tirzepatide-based Mounjaro and Zepbound as well as its oral portfolio, increasing pressure on a market that Novo once dominated more comfortably.
Novo Wants to Be Much More Than an Obesity Company
Doustdar used Monday’s presentation to make the case for a broader Novo.
The company plans to continue expanding its diabetes and obesity businesses while moving further into blood and endocrine disorders, liver disease and cardiovascular disease. The goal is to reduce reliance on one therapeutic franchise as semaglutide exclusivity erodes.
Novo also wants to serve more than 60 million patients worldwide by 2030 and build manufacturing capacity capable of treating 10 times as many people with oral GLP-1 medicines. It expects to maintain a broadly stable operating margin and continue paying what it described as an attractive dividend per share.
The oral market is especially important because it could expand treatment beyond patients willing to use injections. It is also already attracting competition from Lilly.
The distribution side of that fight has increasingly moved into direct-to-consumer and telehealth channels. FinanceFeeds previously examined that shift in its Hims & Hers GLP-1 analysis, including Novo’s move toward branded Wegovy distribution as the market evolves away from compounded semaglutide.
Positive CagriSema Data Could Not Stop the Selling
Monday’s selloff is more striking because Novo also released positive Phase 3 data for CagriSema, one of its most important next-generation obesity candidates.
In a late-stage trial involving patients with diabetes, CagriSema produced estimated average weight loss of 12.4%, compared with 9.1% for a 5 mg dose of Lilly’s tirzepatide. Novo also said the treatment achieved non-inferior blood-sugar reduction.
CagriSema combines cagrilintide with semaglutide and is central to Novo’s planned transition beyond the existing Wegovy franchise. Management is targeting a launch early next year, followed by additional cagrilintide and CagriSema formulations before advancing other next-generation obesity drugs.
Yet the ADR remained down close to 8% hours into the U.S. session.
That suggests Monday’s repricing is not primarily a judgment on one clinical trial. The market is weighing a much larger question: whether a company that grew far faster than conventional pharma during the GLP-1 boom can replace semaglutide, defend pricing against Lilly and generics, and build enough new franchises to keep growing once its most valuable patents begin to disappear.
DKK 150 billion of pipeline sales sounds large in isolation. Monday’s share-price reaction shows investors are comparing it not with zero, but with the earnings power Wegovy and Ozempic have already created.